Idelalisib

Idelalisib is a member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin’s lymphoma and relapsed chronic lymphocytic leukemia. Among its listed roles, it functions as a antineoplastic agent, an apoptosis inducer and an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor. It belongs to the class of purines, an organofluorine compound, a member of quinazolines, an aromatic amine and a secondary amino compound. It is grouped under the following drug class(es): Antineoplastic agents and Kinase inhibitors. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Zydelig and idelalisibum. Its PubChem CID is 11625818.